XOMA is a biopharmaceutical company that discovers, develops and manufactures therapeutic antibodies. These antibodies and other agents are developed in order to treat inflammatory, autoimmune, infections and oncological diseases.
The company has a premier antibody discovery and development platform that incorporates leading antibody phage display libraries and XOMA’s proprietary Human Engineering(tm) and Bacterial Cell Expression (BCE) and manufacturing technologies.
Partnering with companies, such as Novartis AG, Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited, enables XOMA to develop additional antibodies with multi-indication potential. Partnering not only allows XOMA access to new drug targets, but will add substantially to the generation of more revenue for the company.
XOMA was awarded a $65 Million multiple year contract from the National Institute of Allergy and infectious Diseases (NIAII). This contract will support XOMA’ s ongoing development of drug candidates towards clinical trials in the treatment of botulism poisoning, which could be a potentially deadly muscle paralyzing disease.
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Stock Report http://video.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment